Dedicated to transforming the care of people living with rare genetic diseases of obesity

“When Tysen was three he was fifty pounds, when Mike was three he was eighty pounds.”

Mike and Tysen, father and son living with POMC insufficiency obesity (heterozygous)

Joan, wife to Mike and mother to Tysen, both diagnosed with POMC insufficiency obesity (heterozygous)

“I think the biggest thing to try to get people to understand is the constant hunger issue.”

Solomon and Adalissa, siblings living with Bardet-Biedl syndrome

Olivia, Mother of Adalissa and Solomon, both diagnosed with Bardet Biedl syndrome

“When Tysen was three he was fifty pounds, when Mike was three he was eighty pounds.”

Joan, wife to Mike and mother to Tysen, both diagnosed with POMC insufficiency obesity (heterozygous)

Mike and Tysen, father and son living with POMC insufficiency obesity (heterozygous)
“I think the biggest thing to try to get people to understand is the constant hunger issue.”

Olivia, Mother of Adalissa and Solomon, both diagnosed with Bardet Biedl syndrome

Solomon and Adalissa, siblings living with Bardet-Biedl syndrome
Group-1505@2x

We’re focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating hunger and energy expenditure, and consequently, body weight.

An impaired MC4R pathway may lead to rare genetic diseases of obesity, which are characterized by early-onset, severe obesity and a pathological insatiable hunger or hyperphagia. 

We are targeting the MC4R pathway to develop therapeutics for rare genetic diseases of obesity with an integrated precision medicine approach that combined our translational research and clinical development.

Group 1958

Learn about our translational research based on the largest known DNA database focused on obesity.

Group 1958

Learn about our clinical development programs with trials in patients with rare obesities linked to variants in certain genes with strong or very strong relevance to the MC4R pathway.

Our news

2022-11-21T08:00:00

Rhythm Pharmaceuticals Announces ▼IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

2022-11-08T07:05:00

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

2022-11-08T07:00:00

Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update

Dedicated to transforming the care of people living with rare genetic diseases of obesity

OUR COMMUNITY

“When Tysen was three he was fifty pounds, when Mike was three he was eighty pounds.”

Mike and Tysen, father and son living with POMC insufficiency obesity (heterozygous)

Joan, wife to Mike and mother to Tysen, both diagnosed with POMC insufficiency obesity (heterozygous)

“I think the biggest thing to try to get people to understand is the constant hunger issue.”

Solomon and Adalissa, siblings living with Bardet-Biedl syndrome

Olivia, Mother of Adalissa and Solomon, both diagnosed with Bardet Biedl syndrome

“When Tysen was three he was fifty pounds, when Mike was three he was eighty pounds.”

Joan, wife to Mike and mother to Tysen, both diagnosed with POMC insufficiency obesity (heterozygous)

Mike and Tysen, father and son living with POMC insufficiency obesity (heterozygous)
“I think the biggest thing to try to get people to understand is the constant hunger issue.”

Olivia, Mother of Adalissa and Solomon, both diagnosed with Bardet Biedl syndrome

Solomon and Adalissa, siblings living with Bardet-Biedl syndrome

We’re focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger.


By targeting the MC4R pathway, we aim to develop therapeutics
for rare genetic diseases of obesity, including:

Proopiomelanocortin
(POMC) Deficiency Obesity
Leptin Receptor (LEPR)
Deficiency Obesity
Bardet-Biedl
Syndrome (BBS)
Alström
Syndrome
POMC or LEPR
Heterozygous Deficiency Obesity
Smith-Magenis
Syndrome
SRC1 Deficiency
Obesity
MC4R Deficiency
Obesity
SH2B1 Deficiency
Obesity
Our Science

Our news

More News

Now approved for a new indication